Genetic Variants in DNA Mismatch Repair Pathway predict prognosis of Lung Cancer patients with receiving Platinum-Based Chemotherapy.

To investigate the relationships between genetic variants in DNA mismatch repair pathway genes and the prognosis of platinum-based chemotherapy in lung cancer patients. 346 lung cancer patients who received at least two cycles of platinum-based chemotherapy were recruited in this study. A total of 35 single nucleotide polymorphisms in 7 DNA mismatch repair genes were genotyped to investigate their associations with platinum-based chemotherapy prognosis. The results revealed that patients carried rs4608577 TT genotype had a significantly shorter progression free survival than patients with GG or GT genotypes (Additive model: =0.003, OR =0.94, 95% CI =0.33-1.57). Patients with rs707937 TT genotype had a significantly longer overall survival than patients with GG or GT genotypes (Additive model: =0.0003, OR=0.75, 95% CI =0.35-1.14). Eight SNPs and fourteen SNPs were related to progression free survival and overall survival in subgroup analyses, respectively. : Our findings suggest that the rs4608577 and rs707937 may be potential clinical biomarkers for predicting platinum-based chemotherapy prognosis in lung cancer patients.